Director of Product Marketing
Unlearn AI$180,000 - $240,000/year
- Full Time
- Mid-level (3 to 4 years), Senior (5 to 8 years)
About Unlearn AI
Unlearn.AI creates digital twins of patients using artificial intelligence, which are virtual replicas that simulate potential health outcomes. This technology allows healthcare providers to predict how a patient's health may change over time, leading to more informed treatment decisions. The primary clients include healthcare providers and pharmaceutical companies, who can use these digital twins in clinical trials to simulate control groups, potentially speeding up drug development and approval processes. Unlearn.AI differentiates itself by offering a unique simulation technology that reduces the need for actual human control groups, which can save time and resources. The company's goal is to enhance decision-making in patient care and drug development through precise health outcome predictions.
San Francisco, CaliforniaHeadquarters
2017Year Founded
$127.1MTotal Funding
SERIES_CCompany Stage
AI & Machine Learning, HealthcareIndustries
51-200Employees
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Holidays
Commuter Benefits
Paid Parental Leave
Company Equity
Risks
Over-reliance on AI data may lead to inaccuracies in trial outcomes.
Increased competition from companies like Consilx and Aicure could impact market share.
High clinical trial failure rates could affect perception of Unlearn AI's effectiveness.
Differentiation
Unlearn AI's TwinRCT uses digital twins to enhance clinical trial precision.
The company offers TrialPioneer, a free tool for innovative trial design exploration.
Unlearn AI's digital twin technology reduces the need for human control groups.
Upsides
AI in clinical trials market expected to reach $2.74 billion by 2030.
Partnership with ProJenX highlights AI's potential in specific therapeutic areas.
TwinRCT 3.0 enhances decision-making in Phase II trials for better outcomes.
Funding
Total raised$127.09 M
Latest valuation$265.00 M
StageSERIES_C
LATE VC
2/28/2023$15
$265.00 MSERIES B
3/31/2022$50
$250.00 MSERIES A
10/31/2020$3
$60.00 MSEED
7/31/2017$1
$3.25 M